1. Scrip
  2. >>Therapy Areas

5 questions for MSD India's boss

 
• By Anju Ghangurde

MSD India managing director K G Ananthakrishnan's understated style and measured response easily mask the company's strong showing across several product segments and focused approach in markets like India, which is itself currently in a state of flux amid evolving regulations and pressure from the West over intellectual property rights (IPR) issues.

MSD India managing director K G Ananthakrishnan's understated style and measured response easily mask the company's strong showing across several product segments and focused approach in markets like India, which is itself currently in a state of flux amid evolving regulations and pressure from the West over intellectual property rights (IPR) issues.

In response to five critical questions from Scrip, KG (as he is known to friends and pharma bigwigs in the region) underscores the need for India to reassure investors that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.